share_log

Psyched: $100M For MDMA Therapy, VA Funds, 2024 Watchlist, Reform Updates And More

Benzinga ·  Jan 12 16:55

Psychedelics Developer Secures $100M In Series A Funding, Will Support MDMA Approval To Treat PTSD

A decade after it was founded as a wholly-owned subsidiary of theMultidisciplinary Association for Psychedelic Studies (MAPS), MAPS Public Benefit Corporation has securedover $100 million in a Series A private stock sale. The funds will support the final stages of its application for regulatory approval to sell MDMA, also known as ecstasy, as a treatment for post-traumatic stress disorder (PTSD).

MAPS has incubated the only psychedelic-assisted therapy research program that has completed two successful Phase 3 studies and submitted a New Drug Application...

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment